San Francisco, CA — September 10, 2026 – The Cat Health Company (TCHC) today announced positive Phase II clinical results for PURR-001, a once-weekly oral therapeutic designed to treat age-related muscle loss (sarcopenia) in geriatric cats. The study, involving 35 cats aged 10+ years, showed statistically significant gains in skeletal muscle mass compared to placebo over 12 weeks. Additionally, Vetro Solutions has been signed as the lead licensing partner for EU manufacturing and regulatory development.
Clinical Study Design & Results – Study Overview
-
Population: 35 geriatric cats (≥10 years old), mixed breeds, both sexes.
-
Intervention: PURR-001 oral tablet, administered once weekly for 12 weeks.
-
Control: Placebo group (identical appearance, no active ingredient).
-
Primary Endpoint: Change in skeletal muscle mass (measured via DEXA scan).
-
Secondary Endpoints: Body weight, activity levels (accelerometer), owner-reported quality of life.
Key Findings
Source: The Cat Health Company press release, EINPresswire
Mechanism of Action
PURR-001 is a selective androgen receptor modulator (SARM) designed specifically for feline physiology. Unlike traditional anabolic steroids, PURR-001:
-
Targets Muscle Tissue Only: Minimal effects on liver, kidneys, or reproductive organs.
-
Oral Bioavailability: Once-weekly dosing improves compliance vs. daily pills or injections.
-
Safety Profile: No observed adverse events in 12-week study; liver/kidney enzymes remained within normal ranges.
Vetro Solutions Licensing Agreement
Vetro Solutions (EU-based veterinary CDMO) has been appointed as the lead licensing partner for PURR-001 in the European Union. Responsibilities include:
-
Manufacturing: GMP-compliant production of PURR-001 tablets at Vetro’s facility (Bratislava, Slovakia).
-
Regulatory Submission: EMA-CVMP filing expected Q2 2027.
-
Commercialization: Vetro will co-market PURR-001 with TCHC in EU veterinary clinics and online pharmacies.
Financial terms of the licensing deal were not disclosed, but typically include upfront payments, milestones, and royalties (5–15% of net sales).
Market Opportunity: Feline Sarcopenia – Problem Size
-
30–40% of cats aged 10+ years experience clinically significant muscle loss.
-
Untreated sarcopenia leads to frailty, falls, reduced immunity, and earlier mortality.
-
Current solutions: High-protein diets (limited efficacy), physical therapy (owner compliance challenges).
Addressable Market
-
Global geriatric cat population: ~120M cats aged 10+ years.
-
Treatment penetration: 5% by 2030 (conservative estimate).
-
Average annual spend: US$300/cat (medication + monitoring).
-
Total Addressable Market (TAM): US$1.8B by 2030.
Company Profiles
The Cat Health Company (TCHC)
-
Founded: 2021
-
Headquarters: San Francisco, CA, USA
-
Focus: Feline-specific therapeutics (geriatric care, chronic diseases)
-
Pipeline: PURR-001 (sarcopenia), PURR-002 (renal support), PURR-003 (anxiety)
-
Funding: ~US$15M (seed + Series A, undisclosed investors)
-
Team: Ex-Zoetis, Elanco, and academic researchers (UC Davis, Cornell)
Vetro Solutions
-
Founded: 2015
-
Headquarters: Bratislava, Slovakia
-
Focus: Veterinary CDMO (manufacturing, regulatory, commercialization)
-
Clients: 20+ animal health companies (Tier 2–4)
-
Capacity: 50M tablets/year, 10M injectables/year
-
Certifications: EU-GMP, ISO 9001, VICH GL44
Executive Commentary
“PURR-001 represents a paradigm shift in how we manage geriatric cat health. For the first time, we have a therapeutic that directly addresses muscle loss—not just masks symptoms. The 8.2% muscle gain in 12 weeks is clinically meaningful and translates to better mobility, immunity, and longevity.”
— CEO, The Cat Health Company
“Vetro is proud to partner with TCHC on PURR-001. Their focus on feline-specific innovation aligns perfectly with our mission to bring cutting-edge veterinary medicines to EU pet owners. We expect regulatory approval by late 2027 and commercial launch in early 2028.” — CSO, Vetro Solution
Financial Impact & Valuation
Source: Company filings, EINPresswire, analyst estimates
Market Context: Feline Therapeutics Boom
The PURR-001 results align with broader trends in companion animal health:
-
Cat ownership grew 40% globally since 2020 (vs. 25% for dogs).
-
Geriatric cat care market projected to reach US$12B by 2030 (CAGR 11.2%).
-
SARMs in veterinary medicine: First-in-class for cats; human SARMs (e.g., enobosarm) in Phase III for muscle wasting.
 in 35 geriatric cats){kind=link}